1) The document discusses prevention and treatment strategies for oral squamous cell carcinoma (OSCC), a common type of oral cancer.
2) It describes a proposed phase IIB clinical trial called EPOC that would test the drug Erlotinib for preventing oral cancer in high-risk patients.
3) A second proposed clinical trial would test the drug Pioglitazone for treating oral pre-malignant lesions and examining effects on histology, biomarkers, and cancer risk.
9. Erlotinib Prevention of Oral Cancer (EPOC) NCI P01 CA106451 IEN alone Proportion of cases not developing SOM (%) IEN plus cancer history
10. Microdissection DNA extraction PCR Patient eligibility determined within 7 business days Data entered in Web-based database for automatic calculations Determining Protocol Eligibility by LOH DNA fragment separation and quantification